Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

Published:2007-03-01 Issue:5 Volume:13 Page:1367-1373
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Goodman Vicki L.,Rock Edwin P.,Dagher Ramzi,Ramchandani Roshni P.,Abraham Sophia,Gobburu Jogarao V.S.,Booth Brian P.,Verbois S. Leigh,Morse David E.,Liang Cheng Yi,Chidambaram Nallaperumal,Jiang Janet X.,Tang Shenghui,Mahjoob Kooros,Justice Robert,Pazdur Richard

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 428 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Catalyst-free synthesis of some new isatin-thiazole conjugates in water as a green solvent under Ultrasonic condition and evaluation of their antioxidant activity;Tetrahedron;2024-09

2. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment;Microvascular Research;2024-07

3. Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic;Research and Reports in Urology;2024-07

4. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis;The Lancet Oncology;2024-06